1. Pink Sheet

OTC Contraceptive Coverage Plan Includes Broader Rx Mandate

 
• By Michael McCaughan

A proposed rule requiring US insurers to cover non-prescription birth control would also broaden the existing mandate to cover prescription contraceptives at no cost for beneficiaries.

A proposed rule would ensure the OTC oral contraceptive Opill receives insurance coverage at no cost to patients. (Shutterstock)

A Biden Administration proposed rule requiring health insurers to cover OTC contraceptives would also require broader access to prescription birth control products, if it moves forward in 2025.

Key Takeaways
  • A proposed rule on OTC contraceptive coverage also would impact prescription birth control products.

The proposed rule, announced 21 October, feeds into the key reproductive rights theme of Vice President Kamala Harris’ presidential campaign,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Could Study Questioning GLP-1 Cost Savings Impact CMMI Demo Chances?

 
• By Cathy Kelly

The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.

Why Chiesi’s Raxone Faced A Decade-Long Wait For English Funding

 
• By Eliza Slawther

Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.

Europe Eyes First Therapies For PSC And cALD In Latest EMA Drug Filings

 
• By Neena Brizmohun

Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.